Please use this identifier to cite or link to this item: https://repositorio.uca.edu.ar/handle/123456789/11645
Título : Fluoxetine for the symptomatic treatment of Multiple System Atrophy : the MSA-FLUO trial
Autor : Rascol, Olivier 
Cochen De Cock, Valérie 
Pavy-Le Traon, Anne 
Foubert-Samier, Alexandra 
Thalamas, Claire 
Sommet, Agnès 
Rousseau, Vanessa 
Pérez Lloret, Santiago 
Fabbri, Margherita 
Azulay, Jean Philippe 
Corvol, Jean-Christophe 
Couratier, Philippe 
Damier, Philippe 
Defebvre, Luc 
Durif, Franck 
Geny, Christian 
Houeto, Jean-Luc 
Remy, Philippe 
Tranchant, Christine 
Verin, Marc 
Tison, François 
Meissner, Wassilios G. 
Palabras clave : NEUROBIOLOGIAENFERMEDADES NEURODEGENERATIVASENFERMEDAD DE PARKINSONENSAYO CLINICOTRATAMIENTO MEDICOATROFIA MULTISISTÉMICA
Fecha de publicación : 2021
Editorial : Wiley
Cita : Rascol, O., et al. Fluoxetine for the symptomatic treatment of Multiple System Atrophy : the MSA-FLUO trial [en línea]. Postprint del artículo publicado en: Movement Disorders. 2021. doi: 10.1002/mds.28569. Disponible en: https://repositorio.uca.edu.ar/handle/123456789/11645
Resumen : Abstract: Background: There are no effective treatments for multiple system atrophy (MSA). Objective: The objective of this study was to assess the efficacy and safety of the serotonin reuptake inhibitor fluoxetine (40 mg/d) for the symptomatic treatment of MSA. Methods: This was a double-blind, parallel-group, placebo-controlled, randomized trial in patients with "probable" MSA. The primary outcome was the change from baseline to week 12 in the mean total score of the Unified MSA Rating Scale (UMSARS Parts I + II). Secondary outcomes included change from baseline to week 6 in total UMSARS, and change from baseline to week 12 in the Scales for Outcomes in Parkinson Disease-Autonomic Dysfunction, Beck Depression Inventory, and different domains of the MSA-Quality of Life Questionnaire. Exploratory outcomes included change from baseline to week 12 in the UMSARS Parts I and II separately and change from baseline to week 24 in the total UMSARS score. Results: A total of 81 patients were randomly assigned, with no significant difference in the primary outcome (-2.13 units [95% confidence interval, CI, -4.55 to 0.29]; P = 0.08). There was a greater reduction on fluoxetine in the change from baseline to 12-week in UMSARS Part II (exploratory outcome: -1.41 units [95% CI, -2.84; 0.03]; p = 0.05) and in MSA-QoL emotional/social dimension (secondary outcome: -6.99 units [95% CI, -13.40; -0.56]; p < 0.03). A total of 5 deaths occurred (3 on fluoxetine and 2 on placebo). Conclusion: The MSA-FLUO failed to demonstrate fluoxetine superiority over placebo on the total UMSARS score, whereas trends in motor and emotional secondary/exploratory outcomes deserve further investigation.
URI : https://repositorio.uca.edu.ar/handle/123456789/11645
ISSN : 1531-8257
Disciplina: MEDICINA
DOI: 10.1002/mds.28569
Derechos: Acceso abierto. 12 meses de embargo
Appears in Collections:Artículos

Files in This Item:
File Description SizeFormat Existent users please Login
fluoxetine-symptomatic-treatment-atrophy (1).pdf505,36 kBAdobe PDF???org.dspace.app.webui.jsptag.ItemTag.embargo???    Request a copy
Show full item record

Page view(s)

106
checked on Sep 2, 2021

Download(s)

20
checked on Sep 2, 2021

Google ScholarTM

Check


Altmetric


This item is licensed under a Creative Commons License Creative Commons